Should Pacira Pharmaceuticals Inc (NASDAQ:PCRX) investors track the following data?
To the average investor, there are many methods market participants can use to analyze publicly traded companies. Some of the most under-the-radar are hedge fund and insider trading activity. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the top money managers can beat the market by a healthy margin (see just how much).
Just as necessary, optimistic insider trading sentiment is another way to look at the investments you’re interested in. There are lots of incentives for a bullish insider to cut shares of his or her company, but just one, very simple reason why they would behave bullishly. Many empirical studies have demonstrated the useful potential of this method if piggybackers understand where to look (learn more here).
Furthermore, we’re going to examine the latest info surrounding Pacira Pharmaceuticals Inc (NASDAQ:PCRX).
What does the smart money think about Pacira Pharmaceuticals Inc (NASDAQ:PCRX)?
Heading into Q3, a total of 12 of the hedge funds we track were bullish in this stock, a change of 20% from the previous quarter. With hedgies’ positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were boosting their stakes substantially.
When using filings from the hedgies we track, Jacob Gottlieb’s Visium Asset Management had the largest position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX), worth close to $58.3 million, accounting for 1.4% of its total 13F portfolio. Coming in second is Millennium Management, managed by Israel Englander, which held a $16.8 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Other hedge funds that hold long positions include Samuel Isaly’s OrbiMed Advisors, Daniel Arbess’s Xerion and Brian Ashford-Russell and Tim Woolley’s Polar Capital.
As aggregate interest spiked, certain bigger names were breaking ground themselves. Visium Asset Management, managed by Jacob Gottlieb, created the most outsized position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Visium Asset Management had 58.3 million invested in the company at the end of the quarter. Kevin C. Tang’s Tang Capital Management also initiated a $25.8 million position during the quarter. The other funds with brand new PCRX positions are Israel Englander’s Millennium Management, Samuel Isaly’s OrbiMed Advisors, and Daniel Arbess’s Xerion.
What do corporate executives and insiders think about Pacira Pharmaceuticals Inc (NASDAQ:PCRX)?
Insider buying is particularly usable when the company we’re looking at has seen transactions within the past six months. Over the last half-year time frame, Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has experienced zero unique insiders buying, and zero insider sales (see the details of insider trades here).
We’ll check out the relationship between both of these indicators in other stocks similar to Pacira Pharmaceuticals Inc (NASDAQ:PCRX). These stocks are Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Neurocrine Biosciences, Inc. (NASDAQ:NBIX), and Impax Laboratories Inc (NASDAQ:IPXL). This group of stocks belong to the drug manufacturers – major industry and their market caps are closest to PCRX’s market cap.